Warner Chilcott has revealed plans to restructure its operations in Western Europe.
The Dublin-based company expects 500 jobs to be effected by the changes to its operations in Belgium, the Netherlands, France, Germany, Italy, Spain, Switzerland and the UK.
Warner Chilcott’s commercial functions in the UK will not be impacted, the company says, and neither will operations at its headquarters in Dublin, its facilities in Dundalk, Ireland, Larne, Northern Ireland or Weiterstadt, Germany.
The cuts are due to the patent expiry of Actonel (risedronate sodium) in Europe, a product that accounted for around 70% of the company’s Western European revenues in 2010.
“We have conducted a strategic review of our European operations in the context of the recent loss of exclusivity of Actonel in Western Europe,” said Hans van Zoonen, President, Europe/International and Global Marketing.
“The restructuring initiative will allow us to focus on growth opportunities that match Warner Chilcott’s key competitive strengths, including the launches of Atelvia and Loestrin in the United States. We believe this is the appropriate course of action for the company and in the best interest of its shareholders.”
The company also intends to move to a wholesale distribution model in an attempt to cut operational costs.
Restructuring charges of between $120 and $130 million are expected by the company in 2011 and 2012.